Corient Private Wealth LP Has $165.01 Million Stock Holdings in Abbott Laboratories $ABT

Corient Private Wealth LP boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 9.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,818,488 shares of the healthcare product maker’s stock after buying an additional 151,301 shares during the quarter. Corient Private Wealth LP’s holdings in Abbott Laboratories were worth $165,010,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of ABT. California State Teachers Retirement System increased its position in shares of Abbott Laboratories by 9,127.1% during the second quarter. California State Teachers Retirement System now owns 246,828,861 shares of the healthcare product maker’s stock valued at $22,397,251,000 after purchasing an additional 244,153,804 shares during the period. BlackRock Inc. lifted its position in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp lifted its position in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares during the period. Capital International Investors boosted its stake in Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after buying an additional 1,614,706 shares in the last quarter. Finally, J. Stern & Co. LLP increased its holdings in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.2%

Shares of ABT stock opened at $102.08 on Friday. The company has a market capitalization of $176.63 billion, a P/E ratio of 33.03, a P/E/G ratio of 1.92 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average price of $105.60 and a 200 day moving average price of $99.85.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the firm earned $1.26 earnings per share. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of analyst reports. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. UBS Group dropped their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Bank of America decreased their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, TD Cowen reissued a “buy” rating and issued a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.